Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Condition: Urinary Bladder Neoplasms Interventions: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Dru g: Gemcitabine; Drug: Placebo to Pembrolizumab Sponsor: Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials